Literature DB >> 15176951

Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study.

Annie Demers1, Normand McNicoll, Maria Febbraio, Marc Servant, Sylvie Marleau, Roy Silverstein, Huy Ong.   

Abstract

The GHRPs (growth hormone-releasing peptides) are a class of small synthetic peptides known to stimulate GH release through binding of a G-protein-coupled receptor (designated GHS-R). We have found that hexarelin, a hexapeptide member of the GHRPs, binds to another protein identified as CD36, a scavenger receptor that is expressed in various tissues, including monocytes/macrophages and the endothelial microvasculature. CD36 is involved in the endocytosis of oxLDL (oxidized low-density lipoprotein) by macrophages, and in the modulation of angiogenesis elicited by thrombospondin-1 through binding to endothelial cells. To define the binding domain for hexarelin on CD36, covalent photolabelling of CD36 followed by enzymic and chemical degradation of the photoligand-receptor complex was performed. A 8 kDa photolabelled fragment corresponding to the CD36-(Asn132-Glu177) sequence has been identified as the hexarelin-binding site. Chemical cleavage of this fragment with CNBr resulted in the release of the free ligand, suggesting that Met169 is the contact point for the ligand within the receptor binding pocket. We conclude that the binding domain for hexarelin on CD36 overlaps with that for oxLDL, which corresponds to residues Gln155-Lys183 of CD36. Hence hexarelin might interfere with the CD36-mediated uptake of modified lipoproteins by macrophages. This may contribute, at least in part, to the anti-atherosclerotic effect of GHRPs in apolipoprotein E-deficient mice.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15176951      PMCID: PMC1133797          DOI: 10.1042/BJ20040036

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  28 in total

Review 1.  Scavenger receptors, oxidized LDL, and atherosclerosis.

Authors:  A Boullier; D A Bird; M K Chang; E A Dennis; P Friedman; K Gillotre-Taylor; S Hörkkö; W Palinski; O Quehenberger; P Shaw; D Steinberg; V Terpstra; J L Witztum
Journal:  Ann N Y Acad Sci       Date:  2001-12       Impact factor: 5.691

Review 2.  CD36: a class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism.

Authors:  M Febbraio; D P Hajjar; R L Silverstein
Journal:  J Clin Invest       Date:  2001-09       Impact factor: 14.808

3.  Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice.

Authors:  M Febbraio; E A Podrez; J D Smith; D P Hajjar; S L Hazen; H F Hoff; K Sharma; R L Silverstein
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

4.  Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1.

Authors:  B Jiménez; O V Volpert; S E Crawford; M Febbraio; R L Silverstein; N Bouck
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

5.  Identification of peptide ligand-binding domains within the human motilin receptor using photoaffinity labeling.

Authors:  B Coulie; B Matsuura; M Dong; E M Hadac; D I Pinon; S D Feighner; A D Howard; L J Miller
Journal:  J Biol Chem       Date:  2001-07-18       Impact factor: 5.157

6.  Identification and characterization of a new growth hormone-releasing peptide receptor in the heart.

Authors:  V Bodart; J F Bouchard; N McNicoll; E Escher; P Carrière; E Ghigo; T Sejlitz; M G Sirois; D Lamontagne; H Ong
Journal:  Circ Res       Date:  1999-10-29       Impact factor: 17.367

Review 7.  Growth hormone-releasing peptides and the cardiovascular system.

Authors:  G Muccioli; F Broglio; M R Valetto; C Ghè; F Catapano; A Graziani; M Papotti; G Bisi; R Deghenghi; E Ghigo
Journal:  Ann Endocrinol (Paris)       Date:  2000-02       Impact factor: 2.478

8.  Growth hormone secretagogue binding sites in peripheral human tissues.

Authors:  M Papotti; C Ghè; P Cassoni; F Catapano; R Deghenghi; E Ghigo; G Muccioli
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

9.  Identification of a pituitary growth hormone-releasing peptide (GHRP) receptor subtype by photoaffinity labeling.

Authors:  H Ong; N McNicoll; E Escher; R Collu; R Deghenghi; V Locatelli; E Ghigo; G Muccioli; M Boghen; M Nilsson
Journal:  Endocrinology       Date:  1998-01       Impact factor: 4.736

Review 10.  Biologic activities of growth hormone secretagogues in humans.

Authors:  E Ghigo; E Arvat; R Giordano; F Broglio; L Gianotti; M Maccario; G Bisi; A Graziani; M Papotti; G Muccioli; R Deghenghi; F Camanni
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.925

View more
  33 in total

Review 1.  Therapeutic strategies to deplete macrophages in atherosclerotic plaques.

Authors:  Inge De Meyer; Wim Martinet; Guido R Y De Meyer
Journal:  Br J Clin Pharmacol       Date:  2012-08       Impact factor: 4.335

Review 2.  CD36: implications in cardiovascular disease.

Authors:  Maria Febbraio; Roy L Silverstein
Journal:  Int J Biochem Cell Biol       Date:  2007-03-23       Impact factor: 5.085

Review 3.  GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products.

Authors:  Valeria Guglielmi; Paolo Sbraccia
Journal:  Eat Weight Disord       Date:  2016-12-31       Impact factor: 4.652

4.  Identification of Inhibitors of CD36-Amyloid Beta Binding as Potential Agents for Alzheimer's Disease.

Authors:  Deborah Doens; Pedro A Valiente; Adelphe M Mfuh; Anh X T Vo; Adilia Tristan; Lizmar Carreño; Mario Quijada; Vu T Nguyen; George Perry; Oleg V Larionov; Ricardo Lleonart; Patricia L Fernández
Journal:  ACS Chem Neurosci       Date:  2017-02-15       Impact factor: 4.418

5.  p53 is an important regulator of CCL2 gene expression.

Authors:  X Tang; M Asano; A O'Reilly; A Farquhar; Y Yang; S Amar
Journal:  Curr Mol Med       Date:  2012-09       Impact factor: 2.222

Review 6.  CD36 in chronic kidney disease: novel insights and therapeutic opportunities.

Authors:  Xiaochun Yang; Daryl M Okamura; Xifeng Lu; Yaxi Chen; John Moorhead; Zac Varghese; Xiong Z Ruan
Journal:  Nat Rev Nephrol       Date:  2017-09-18       Impact factor: 28.314

7.  Insulin-like actions of glucagon-like peptide-1: a dual receptor hypothesis.

Authors:  Eva Tomas; Joel F Habener
Journal:  Trends Endocrinol Metab       Date:  2009-12-16       Impact factor: 12.015

8.  A concerted kinase interplay identifies PPARgamma as a molecular target of ghrelin signaling in macrophages.

Authors:  Annie Demers; Véronique Caron; Amélie Rodrigue-Way; Walter Wahli; Huy Ong; André Tremblay
Journal:  PLoS One       Date:  2009-11-04       Impact factor: 3.240

9.  Sulfo-N-succinimidyl oleate (SSO) inhibits fatty acid uptake and signaling for intracellular calcium via binding CD36 lysine 164: SSO also inhibits oxidized low density lipoprotein uptake by macrophages.

Authors:  Ondrej Kuda; Terri A Pietka; Zuzana Demianova; Eva Kudova; Josef Cvacka; Jan Kopecky; Nada A Abumrad
Journal:  J Biol Chem       Date:  2013-04-18       Impact factor: 5.157

Review 10.  CD36: a multi-modal target for acute stroke therapy.

Authors:  Sunghee Cho; Eunhee Kim
Journal:  J Neurochem       Date:  2009-05       Impact factor: 5.372

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.